Skip to main content

Advertisement

Fig. 2 | Chinese Journal of Cancer

Fig. 2

From: Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Fig. 2

Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS) probability of mCRC patients treated with famitinib and placebo. a the median PFS in the famitinib group was significantly longer than that in the placebo group (P = 0.004); b there is no significant difference in the median OS between the two groups

Back to article page